The Study of How Long Participants Stay in the Hospital After Receiving Apixaban for a Blood Clot in the Lung

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Pulmonary Thromboembolism; Pulmonary Embolism (PE)

Treatments: Other: Non-Interventional

Study type: Observational

Funder types: Industry

Identifiers

NCT03595891

CV185-640

Details and patient eligibility

About

A study based on a chart review of participants that presented with a sudden blood clot in the lung

Enrollment: 660 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adults participants at date of admission
• Primary presentation consistent with PE followed by objectively-confirmed acute PE
• Received anti-coagulation upon diagnosis of PE during study period and in receipt of anti-coagulation at discharge

Exclusion criteria

• PE diagnosed during a hospital admission for a reason other than PE during the study period
• Patients receiving anticoagulation at the time of presentation
• Patients presenting outside the defined study period

Other protocol defined inclusion/exclusion criteria could apply

Trial design

660 participants in 2 patient groups

Adult with acute PE before the introduction of apixaban

Treatment:

Other: Non-Interventional

Adult with acute PE after the introduction of apixaban

Treatment:

Other: Non-Interventional